DeepMed Research

Stallergenes Greer

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Established: 2015-01-01

Employees: 1K

Market Cap: -

Website: http://www.stallergenesgreer.com/

Clinical Trials

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

Phase 1

Completed

Conditions: House Dust Mite Allergy
Asthma

Interventions: Biological: SLIT tablets of house dust mite allergen extracts
Biological: Matching placebo

First Posted Date: 2012-05-31

Last Posted Date: 2014-07-01

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 94

Registration Number: NCT01608243

Locations: 🇫🇷
CHU Arnaud de Villeneuve, Montpellier, France

Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model

Phase 2

Completed

Conditions: Allergic Rhinitis Due to House Dust Mite

Interventions: Biological: 500IR
Other: Placebo
Biological: 100IR
Biological: 300IR
Drug: 100 IR house dust mites allergen extract tablet
Drug: 300 IR house dust mites allergen extract tablet
Drug: 500 IR house dust mites allergen extract tablet
Drug: Placebo tablet

First Posted Date: 2012-02-06

Last Posted Date: 2025-02-04

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 355

Registration Number: NCT01527188

Locations: 🇨🇦
Cetero Research, Mississauga, Ontario, Canada

Safety and Tolerability Study of Ragweed SLIT Tablets

Phase 1

Completed

Conditions: Rhinitis, Allergic, Seasonal
Ragweed Pollen Allergy

Interventions: Drug: Sublingual tablet of ragweed pollen allergen extract

First Posted Date: 2010-10-20

Last Posted Date: 2010-11-07

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 60

Registration Number: NCT01224834

Locations: 🇭🇺
DRC Drug Research Center, Balatonfüred, Hungary

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children

Phase 3

Terminated

Conditions: Allergic Rhinitis Due to Dust Mite

Interventions: Drug: 300 IR house dust mites allergen extract tablet
Drug: Placebo tablet

First Posted Date: 2010-09-10

Last Posted Date: 2025-02-11

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 471

Registration Number: NCT01199133

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Phase 3

Completed

Conditions: Allergic Rhinitis Due to Grass Pollens

Interventions: Drug: 300 IR
Drug: Placebo

First Posted Date: 2009-08-10

Last Posted Date: 2016-05-19

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 473

Registration Number: NCT00955825

Locations: 🇺🇸
Allergy & Asthma Specialists, PSC, Owensboro, Kentucky, United States
🇺🇸
Montana Medical Research, Missoula, Montana, United States
🇺🇸
Clinical Research of the Ozarks, Inc., Columbia, Missouri, United States

and more 16 locations

Study of rBet v1 Tablets

Phase 2

Completed

Conditions: Birch Pollen-related Rhinoconjunctivitis
Rhinitis, Allergic, Seasonal

Interventions: Biological: Placebo
Biological: rBet v 1

First Posted Date: 2009-05-14

Last Posted Date: 2013-06-27

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 483

Registration Number: NCT00901914

Locations: 🇩🇰
National University Hospital - Allergy Unit 4222, Copenhagen, Denmark
🇫🇮
Helsingin yliopistollinen keskussairaala, Helsinki, Finland
🇫🇷
NHC, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

and more 5 locations

Safety and Tolerability Study of rBet v1 SLIT Tablets

Phase 1

Completed

Conditions: Birch Pollen-Related Rhinoconjunctivitis
Rhinitis, Allergic, Seasonal

Interventions: Biological: Placebo
Biological: rBet v 1

First Posted Date: 2009-04-29

Last Posted Date: 2009-04-29

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 55

Registration Number: NCT00889460

Locations: 🇩🇰
National University Hospital - Allergy Unit 4222, Copenhagen, Denmark

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Phase 3

Completed

Conditions: Primary Disease

Interventions: Drug: 300 IR
Drug: Placebo

First Posted Date: 2008-12-05

Last Posted Date: 2016-05-25

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 381

Registration Number: NCT00803244

Locations: 🇫🇷
Hop Montauban, Montauban, France
🇫🇷
Cab medical, Orange, France
🇫🇷
Stallergenes Sa, Antony, France

and more 3 locations

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

Phase 2

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: 300 IR house dust mites allergen extract tablet
Drug: Placebo tablet
Drug: 500 IR house dust mites allergen extract tablet

First Posted Date: 2008-05-08

Last Posted Date: 2016-05-19

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 509

Registration Number: NCT00674700

A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites

Phase 3

Completed

Conditions: Allergy

Interventions: Drug: Staloral

First Posted Date: 2008-04-17

Last Posted Date: 2011-10-12

Lead Sponsor: Stallergenes Greer

Target Recruit Count: 484

Registration Number: NCT00660452

Locations: 🇨🇳
Peking Union Medical College Hospital -, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy